ODB lists Afinitor (everolimus) for NETs of Gastrointestinal or Lung origin
We are pleased to announce that Ontario Drug Benefit (ODB) has listed Afinitor (everolimus) for the treatment of patients with GI/Lung NET, effective November 20, 2017 through the Exceptional Access [...]